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PURPOSE. Three common sequence variants in the lysyl oxidase-
like 1 (LOXL1) gene were recently associated with both
pseudoexfoliation (PEX) and pseudoexfoliation glaucoma
(PEXG) in populations from Iceland and Sweden. In this study,
the genetic association of these variants was investigated in
patients with PEX or PEXG of German and Italian descent.
METHODS. The three LOXL1 single-nucleotide polymorphisms
(SNPs), one intronic (rs2165241) and two nonsynonymous
coding SNPs (rs1048661: R141L and rs3825942: G153D) were
genotyped in a total of 726 unrelated patients with PEX or
PEXG (517 Germans and 209 Italians) and 418 healthy subjects
who had normal findings in repeated ophthalmic examina-
tions, and a genetic association study was performed.
RESULTS. Strong association with the three LOXL1 common
sequence variants was seen in both the PEX and PEXG patient
groups independent of their geographic origin (rs2165241,
combined OR  3.42, P  1.28  1040; rs1048661, OR 
2.43, P  2.90  1019; and rs3825942, OR  4.87, P 
8.22  1023). Similarly, the common frequent haplotype
(G-G) composed of the two coding SNPs (rs1048661 and
rs3825942) was strongly associated in PEX and PEXG cohorts
of both populations with the disease (combined OR  3.58,
P  5.21 1043).
CONCLUSIONS. Genetic variants in LOXL1 confer risk to PEX in
German and Italian populations, independent of the presence
of secondary glaucoma, confirming findings in patients from
Northern Europe. (Invest Ophthalmol Vis Sci. 2008;49:
1459–1463) DOI:10.1167/iovs.07-1449
Pseudoexfoliation glaucoma (PEXG) is the most commonidentifiable cause of open-angle glaucoma, accounting for
approximately 25% of all open-angle glaucoma worldwide and
most cases of glaucoma in some countries.1 For instance, it
accounts for 77% of all open-angle glaucoma in the eastern
region of the Arabian peninsula.2 Compared with primary
open-angle glaucoma (POAG), PEXG has a more serious clinical
course, a more rapid progression, and a worse prognosis and is
more difficult to treat.3
The underlying disorder, PEX syndrome, is an age-related
systemic disease of the extracellular matrix characterized by
the multifocal production and progressive accumulation of a
fibrillar extracellular material in intra- and extraocular tissues
that is either the result of an excessive production or insuffi-
cient breakdown or both.4 Active involvement of the trabecu-
lar meshwork in this matrix process may lead to glaucoma
development in about half of patients with PEX. Although its
exact etiology and pathogenesis are still unknown, recent
molecular biological and biochemical data support the patho-
genetic concept of PEX syndrome as a type of stress-induced
elastic microfibrillopathy, associated with the excessive pro-
duction and abnormal aggregation of elastic microfibrils by a
variety of potentially elastogenic cell types.5,6 Although a
cause-and-effect relationship of PEX and other systemic dis-
eases has not been established, increasing evidence suggests
that PEX syndrome is associated with cardiovascular and cere-
brovascular diseases.6,7
PEX syndrome occurs in all geographic regions worldwide,
with reported prevalence rates averaging approximately 10%
to 20% of the general population over age 60.8 Several lines of
evidence show the tendency for the condition to cluster geo-
graphically and in certain racial or ethnic subgroups in differ-
ence prevalence,9 family aggregation and an increased risk of
PEX in relatives of affected subjects suggest underlying genetic
factors that predispose to this condition.10,11
Recently, a genome-wide association study detected three
common SNPs on chromosome 15, area q24.1, in the lysyl
oxidase-like 1 (LOXL1) gene, which is associated both with
PEX and PEXG in Icelandic and Swedish populations.12 Strik-
ingly, the results indicate that these gene polymorphisms are
major susceptibility variants for PEX and support the notion
that they confer risk of glaucoma mainly through PEX, as no
association was observed in glaucoma patients only. Moreover,
the disease-associated polymorphisms appeared to be present
in virtually all patients with PEXG within the populations
studied.12
The product of LOXL1 is a member of the lysyl oxidase (LO)
protein family involved in the cross-linking of collagen and
elastin in the extracellular space thereby stabilizing and insolu-
bilizing polymeric elastin and collagen. It is required for elastic
tissue homeostasis and is ubiquitously expressed.13,14 LOXL1-
deficient mice showed reduced elastin content in different
main organs and also had pelvic organ prolapse, enlarged
airspaces of the lung, and skin and vascular abnormalities, but
to our knowledge no eye phenotype was reported.15 Although
LOXL1 is responsible for PEX in non-Scandinavian populations
as well, its exact role in the pathogenesis of the disease remains
to be determined.
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Our study was designed to investigate association of three
common LOXL1 polymorphisms with PEX and PEXG in two
well-characterized patients’ cohorts originating from Germany
and Italy.
METHODS
Study Populations
The study was approved by the ethics review boards of the Medical
Faculty of the University of Erlangen-Nuremberg (Germany) and of the
Monfalcone Hospital (Italy) and was in accordance with the tenets of
the Declaration of Helsinki. All subjects gave informed consent before
entering the study.
The group of 726 patients with PEX consisted of 517 subjects of
German and 209 subjects of Italian origin (European). Exact composi-
tion, age, and sex distribution data of the two different patients’
cohorts are reported below (Table 1). No significance difference re-
garding age and sex distribution between the groups of patients was
noted. All German individuals underwent standardized clinical exami-
nations for PEX at the Ophthalmologic Department of the University of
Erlangen-Nuremberg (Erlangen, Germany), whereas all Italian patients
were examined at the Ophthalmologic Department of the Hospital in
Monfalcone (Italy) with identical clinical examinations. Unequivocal
agreement was found between the clinical investigators CYM in Ger-
many and DP in Italy. All patients recruited with PEX syndrome had to
have manifest PEX material on the anterior capsule and pupillary
margin in mydriasis, clearly visible on slitlamp biomicroscopy. Second-
ary open-angle glaucoma due to PEX syndrome was defined, if elevated
intraocular pressure (IOP), an open chamber angle, characteristic vi-
sual field defects in computed perimetry and characteristic glaucoma-
tous disc atrophy were found in the presence of manifest PEX deposits
on the anterior lens capsule and/or pupillary margin.
A total of 418 healthy subjects were recruited. Three hundred
forty-eight control individuals were of German and 70 were of Italian
origin. Both groups were recruited from the same geographic regions
as the patients, respectively. In addition, control subjects underwent
ophthalmic examination and matched for age and sex (Table 1). Over-
all healthy individuals had IOP below 20 mm Hg, no glaucomatous disc
damage, no PEX material deposits on anterior lens capsule and/or
pupillary margin, no criteria indicating early or suspect PEX (e.g.,
atrophy of the iridal pigment epithelium at the pupillary margin,
secondary melanin dispersion in the chamber angle and anterior cham-
ber after dilation of the pupil, no dewlike condensation on the ante-
rior, lens capsule, and normal mydriasis) and no family history of PEX
and glaucoma. Visual acuity was at least 0.8, and the optic media were
clear for ophthalmic examination.
DNA Extraction and Genotyping
Genomic DNAs were extracted in the same laboratory from peripheral
blood leukocytes of the 726 patients with PEX and 418 control indi-
viduals with automated techniques (AutoGenFlex 3000; AutoGen, Hol-
liston, MA) using DNA chemistry (Flexigene; Qiagen, Hilden, Ger-
many). SNP rs2165241 was genotyped with a predeveloped assay
(TaqMan; Applied Biosystems [ABI], Foster City, CA). Reactions were
prepared according to manufacturer’s instructions and performed on a
sequence detection system (Prism 7900HT; ABI), by using standard
thermal cycling conditions. The two nonsynonymous SNPs rs3825942
and rs1048661 were genotyped through direct sequencing as the
corresponding assays failed. Purified PCR products (AMPure; Agen-
court Bioscience, Beverly MA, purified on a Biomek NX96 platform;
Beckman Instruments, Fullerton, CA) were sequenced using dye ter-
mination chemistry (Prism Fluorescent Dye Termination; ABI). Purified
sequence reactions (CleanSEQ; Agencourt Bioscience) were resolved
on a sequence analyzer (3730xl Sequence Analyzer; ABI) and analyzed
with genome assembly software (SEQMAN software; DNAStar, Madi-
son, WI). The average genotyping rate was 98.5%.
Statistical Analysis
Hardy-Weinberg equilibrium for all SNPs was confirmed in the case and
control samples by using Haploview.16 Analysis of association by using
allele counts and linkage disequilibrium-based haplotypes, was also
performed with Haploview, which uses 2 statistics for assessing hap-
lotype association (ver. 3.2).16 P  0.05 was considered statistically
significant. Odds ratio (OR) and 95% confidence interval (CI) were
calculated with opensource software written by D. J. R. Hutchon
(http://www.hutchon.net/ConfidOR.htm).17
RESULTS
Analysis of the single genotypes of the three LOXL1 common
sequence variants (rs2165241TC, rs1048661GT, and
rs3825942GA) in the PEX and PEXG patients from Germany
and Italy, as well as respective control subjects are shown in
Table 2 where differences in genotype distribution among
patients and control subjects were detected in both popula-
tions. Strong association with the risk allele of each individual
SNP (rs2165241T, rs1048661G, and rs3825942G) was ob-
served in German samples of both PEX and PEXG, similar to
that found in the Icelandic and Swedish samples12 with ORs
between 2.49 and 3.26 (Table 3). Similar results were obtained
in the Italian group with ORs ranging from 2.09 to 3.71. No
ORs could be calculated for rs3825942 (G153D), as all Italian
patients analyzed were homozygous for the G allele at this SNP.
Overall, allele frequencies in both populations in cases and
control subjects were quite similar to those previously re-
ported in Scandinavian patients.12 Thus, we combined the
results from German and Italian patients groups and observed
a maximum OR  2.43 (P  2.90  1019) for allele G of SNP
rs1048661 and a maximum OR  4.87 (P  8.22  1023) for
allele G of SNP rs3825942 (Table 3). It is also to note that, in
both populations, the individual ORs of each single allele were
similar for PEXG and PEX syndrome (Table 3) showing that the
risk of glaucoma is due to the presence of PEX.
Haplotype analysis derived from allelic combination of the
two nonsynonymous SNPs, rs1048661 and rs3825942, which
are in complete linkage disequilibrium (D  1) detected only
TABLE 1. Composition, Age, and Sex Distribution in Patients and Healthy Subjects
Patients
PEX
(n)
PEXG
(n)
Age
Female MaleOrigin n Mean  SD Minimum Maximum
Patients
German 517 206 311 76.6  8.51 49 99 287 230
Italian 209 76 133 78.3  7.72 60 101 127 82
Controls
German 348 — — 73.9  6.4 51 92 196 151
Italian 70 — — 75.2  7.37 57 90 45 25
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three of the four possible haplotypes (G-G; T-G, and G-A), both
in the German and Italian groups (Table 4). Similar to the data
from the Scandinavian population12 the haplotype (T-A) was
not seen in our samples. Among the three haplotypes observed
(G-G, T-G, and G-A), the main common haplotype in the pop-
ulation (G-G) is the only overrepresented one in all patient
groups of the two population and independent of the occur-
rence of glaucoma (Table 4). Thus, we calculated a combined
OR for PEX and PEXG in German and Italian patients (OR 
3.58; P 5.21 1043). Moreover, two copies of the high-risk
haplotype (G-G homozygosity) were identified in 66.1% of our
total patients’ cohorts compared with 27.3% of our complete
control subjects (OR  5.2, 95% CI  3.99–6.78; P  1.7 
1037). Our results clearly confirm the genetic association
previously seen in Scandinavian populations.
DISCUSSION
Our results convincingly show a genetic association of both
PEX and PEXG with an intronic and two nonsynonymous
coding SNPs of the LOXL1 gene as well as the haplotype
encompassing the latter two in two independent European
populations from Germany and Italy, confirming those initially
detected in Scandinavian populations.12 A common haplotype
(G-G) with a frequency of approximately 50% in control sub-
jects is strongly associated with both PEX and PEXG in German
and Italian populations and seems to be the strongest associ-
ated risk factor. Our findings indicate that this risk factor is
common to several European populations, which is in agree-
ment with the common disease-common haplotype hypothe-
sis.18,19 In addition, as the frequency of the two risk alleles, as
well as of the risk haplotype, in PEX cases without glaucoma is
similar to that of PEX cases with glaucoma (Tables 3, 4) in both
population, these data support the notion that these SNPs
confer risk of glaucoma mainly through PEX.
The precise etiology and pathogenesis of PEX syndrome,
however, remain poorly understood. Available immunohisto-
chemical, biochemical, and molecular biological data strongly
support the current concept that the fibrillar PEX deposits
involve components of elastic fibers and microfibrils and that
PEX syndrome is an elastic microfibrillopathy associated with
an excessive production and aggregation of elastic microfi-
brils6 or with an abnormal regulation of elastin synthesis.7,20,21
The functional significance of LOXL1 in these PEX-associ-
ated elastotic processes is still unknown. To date apart from
expression in lamina cribrosa cells and optic nerve head astro-
cytes,22 LOXL1 has been detected throughout the body in
various organs, such as adult human lung, kidney, liver, heart,
and muscle tissue,23,24 all of which are known to be affected by
accumulations of PEX material.7 Recent studies have demon-
strated that LOXL1 is specifically targeted to sites of elastogen-
esis by binding of the LOXL1 propeptide to both tropoelastine
TABLE 2. Single Genotype Counts
Study Population (n)
rs2165241 rs1048661 rs3825942
CC CT TT GG GT TT GG GA AA
Germany
Controls (348) 98 158 84 136 165 41 250 78 18
PEXG (311) 23 96 190 218 86 7 284 25 2
PEX (206) 18 76 109 126 69 9 185 15 3
Italy
Controls (70) 19 29 20 34 29 7 49 17 4
PEXG (133) 3 47 82 84 44 2 130 0 0
PEX (76) 2 26 45 53 22 1 76 0 0
Genotype counts are provided for the three common sequence risk variants, rs2165241T  C, rs1048661G  T, and rs3825942G  A, in
German (n  517) and Italian (n  209) patients and respective controls subjects.
TABLE 3. ORs of LOXL1 Single-Risk Alleles at SNPS rs2165241 T, rs1048661 G, and rs3825942 G in PEX and PEXG from Germany and Italy
Study Groups (n)
rs2165241 T
rs1048661 G
LOXL1*141R
rs3825942 G
LOXL1*153G
Frq. OR (95% CI) P Frq. OR (95% CI) P Frq. OR (95% CI) P
Germany
Controls (348) 0.482 0.644 0.857
PEX combined (517) 0.752 3.26 (2.65–4.01) 6.77  1030 0.818 2.49 (1.99–3.12) 4.32  1016 0.951 3.26 (2.28–4.66) 1.21  1011
PEXG (311) 0.770 3.60 (2.83–4.58) 1.74  1026 0.839 2.89 (2.21–3.77) 1.40  1015 0.953 3.41 (2.22–5.24) 4.78  109
PEX (206) 0.724 2.82 (2.16–3.68) 7.04  1015 0.787 2.04 (1.54–2.71) 7.08  107 0.948 3.06 (1.87–4.99) 3.15  106
Italy
Controls (70) 0.515 0.693 0.821
PEX combined (209) 0.798 3.71 (2.44–5.63) 2.19  1010 0.825 2.09 (1.35–3.25) 0.0009 1.000  1.66  1018
PEXG (133) 0.799 3.75 (2.38–5.91) 5.18  109 0.815 1.96 (1.22–3.15) 0.0053 1.000  1.96  1012
PEX (76) 0.795 3.64 (2.15–6.16) 8.79  107 0.842 2.36 (1.34–x4.16) 0.0024 1.000  5.08  108
Combined
Controls (418) 0.488 0.652 0.851
PEX combined (726) 0.765 3.42 (2.85–4.11) 1.28  1040 0.820 2.43 (2.00–2.97) 2.90  1019 0.965 4.87 (3.46–6.85) 8.22  1023
PEXG (444) 0.779 3.70 (3.00–4.57) 1.43  1035 0.832 2.64 (2.10–3.32) 1.89  1017 0.967 5.15 (3.39–7.82) 4.26  1017
PEX (282) 0.743 3.03 (2.40–3.84) 5.90  1021 0.802 2.16 (1.67–2.78) 1.75  109 0.962 4.48 (2.78–7.21) 3.02  1011
SNP rs2165241 is located in the first intron of LOXL1, rs1048661 and rs3825942 cause amino-acid changes R141L and G153D, respectively.
Frq., frequency; OR , OR infinity.
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and fibulin-5 and that these interactions are essential for direct-
ing the deposition of the enzyme onto elastic fibers.14 The two
risks coding SNPs (rs1048661 and rs382542) are located in the
N-terminal part of pro-LOXL1 which was suggested to be crit-
ical in ensuring proper enzyme activation and in identifying the
appropriate substrate that is to be acted on by the enzyme.14,15
As consequence these SNPs may influence targeting of pro-
LOXL1 to tropoelastin or mediate the interaction of LOXL1
with other substrates.
Analyses of adipose tissues have shown that the expression
of LOXL1 is decreased by 7.7% per risk allele of SNP rs1048661
(R141L),12 which is a small change, but in a late-onset disease
it could be relevant. It is notable, however, that the risk allele
G of rs3825942 (G153D), the variant that confers the greater
risk in all population studies so far and interestingly the only
one present in the Italian patient cohort, has no effect on
LOXL1 expression, at least in adipose tissues. Nevertheless,
inadequate levels of LOXL1 in systemic and ocular tissues
could predispose to an impaired elastin homeostasis and elas-
totic processes. Alternatively, sequence variations in the
LOXL1 propeptide may alter the substrate specificity of LOXL1
and may lead to abnormal cross-linking, aggregation and insolu-
bilization of elastic microfibrillar components into the typical
PEX fibers.
Further studies correlating the genetic variants in the
LOXL1 and ocular tissue changes associated with PEX are now
needed to confirm the association of SNPs rs1048661 and
rs382542 with this condition and to elucidate its functional
consequences.
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